Overview
Donor: | BrightFocus Foundation |
Application procedure: | Concept Note |
Donor base: | United States |
Reference number: | - |
Eligible applicants: | Individual |
Deadline: | 25.07.2024 |
Financial details
Grant size: | Medium - up to $1,000,000 |
Minimum grant size: | - |
Total available budget: | - |
Funding type: | Grants |
Maximum grant size: | 600.000$ |
Funding ratio: | up to 100% |
Sectors
- Health
- Research, Technology & Innovation
Project Locations
Africa
Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Democratic Republic of the Congo, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea Bissau, Ivory Coast, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Republic of the Congo, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zambia, Zimbabwe
America
Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, French Guiana, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
Asia
Afghanistan, Azerbaijan, Bahrain, Bangladesh, Bhutan, Brunei, Cambodia, China, East Timor, India, Indonesia, Iran, Iraq, Israel, Japan, Jordan, Kazakhstan, Korea, Kuwait, Kyrgyzstan, Laos, Lebanon, Malaysia, Maldives, Mongolia, Myanmar, Nepal, North Korea, Oman, Pakistan, Palestine, Philippines, Qatar, Russian Federation, Saudi Arabia, Singapore, South Korea, Sri Lanka, Syria, Taiwan, Tajikistan, Thailand, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan, Vietnam, West Bank and Gaza, Yemen
Europe
Albania, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Georgia, Hungary, Kosovo, Latvia, Lithuania, Moldova, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia, Ukraine
Pacific
Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, Palau, Papua New Guinea, Samoa, Solomon Islands, Tonga, Tuvalu, Vanuatu
Description
1) Objective
BrightFocus accepts investigator initiated proposals related to developing treatments, preventions, and cures for glaucoma, macular degeneration, and Alzheimer’s disease.
- Postdoctoral Fellowship: Candidates must hold an MD, PhD, DVM, DO, OD or equivalent degree received no more than four years before the time of application. For clinician scientists, this application should be submitted within two years after completion of their final clinical training.
- New Investigator Grant: This research grant program is restricted to new and early investigators who have received their MD, PhD or equivalent degree within the past 10 years at the time of application. Applicant must serve as the Principal Investigator on the project and have independent laboratory space.
- Innovative Research Grant: High-risk/high-gain age-related macular degeneration research. We hope to attract established investigators to apply for this support, but the aims of the application must contain outside-the-box ideas that are novel in the field.
2) Eligibility
Candidates must hold an MD, PhD, DVM, DO, OD or equivalent degree received no more than four years before the time of application. For clinician scientists, this application should be submitted within two years after completion of their final clinical training. Exceptions to the above four-year and two-year eligibility period will be considered under unusual circumstances. Candidates must submit a written exception request to BrightFocus and obtain approval before applying.
3) Location
BrightFocus supports U.S. domestic and international research proposals.
4) Budget
Grants may range from $200,000-$600,000.
5) Application
Letter of Intent FY22 is due 25 July 2024.